Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemokine-Modulatory Regimen in Recurrent Resectable Colorectal Cancer
NCT01545141Phase 2Terminated
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Oct 2012
- Primary completion
- Apr 2016
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of rintatolimod in colorectal cancer (CRC), sponsored by Roswell Park Comprehensive Cancer Center. Started Oct 2012; status: terminated.
02
Drugs
rintatolimod
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01545141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01545141.